|
| Status |
Public on May 05, 2022 |
| Title |
H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
The study was performed to identify the role of H3K9 methylation in prostate cancer. This experiment was conducted to determine the genomic localization of H3K9me2 and H3K9me3 in naïve, short-term antiandrogen treated and antiandrogen resistant prostate cancer cells.
|
| |
|
| Overall design |
Chromatin immunoprecipitation DNA-sequencing (ChIP-seq) for histone modifications H3K9me2 and H3K9me3 in naïve LNCaP, short-term antiandrogen treated LNCaP and LNCaP EnzR cells.
|
| |
|
| Contributor(s) |
Baratchian M, Tiwari R, Sharifi N |
| Citation(s) |
35584120 |
| |
| Submission date |
May 05, 2022 |
| Last update date |
Jun 23, 2022 |
| Contact name |
Vladimir Makarov |
| E-mail(s) |
makarov@ccf.org
|
| Phone |
2162879971
|
| Organization name |
CLEVELAND CLINIC LERNER COM-CWRU
|
| Street address |
9500 Euclid Ave
|
| City |
Cleveland |
| State/province |
OH |
| ZIP/Postal code |
44195 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (8)
|
|
| Relations |
| BioProject |
PRJNA835482 |
Less...
More...